A Phase 2 clinical trial testing obexelimab in adults with relapsing types of multiple sclerosis is now recruiting ...

NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors ...

Earnings reflect R&D investments in 2024 including the acquisition of Kate Therapeutics, Mariana Oncology, IFM Due, MorphoSys AG, Calypso Biotech BV, and SanReno Therapeutics. Additionally, as the ...

Novartis AG (NVS) reports robust financial performance with significant product sales growth, while addressing potential ...

European shares closed at a record high on Friday (Jan 31), led by technology stocks, as earnings from companies such as ...

Smiths Group propped up the FTSE 100, rising more than 14% after the opening bell following news it had responded to activist ...

Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals ...

In the corporate sector, Novartis (SIX: NOVN) stock rose 4% after Swiss drugmaker reported strong fourth-quarter results ...

Novartis’ results show the firm humming along nicely in 2024, with sales driven by continued strong performance from its ...

Pharma giant Novartis comfortably beat market forecasts with its fourth-quarter results on Friday, with the Swiss firm ...

Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's ...